ATE514087T1 - Glycokonjugate und ihre verwendung als potentielle impfstoffe gegen eine infektion mit shigella flexneri - Google Patents
Glycokonjugate und ihre verwendung als potentielle impfstoffe gegen eine infektion mit shigella flexneriInfo
- Publication number
- ATE514087T1 ATE514087T1 AT04744281T AT04744281T ATE514087T1 AT E514087 T1 ATE514087 T1 AT E514087T1 AT 04744281 T AT04744281 T AT 04744281T AT 04744281 T AT04744281 T AT 04744281T AT E514087 T1 ATE514087 T1 AT E514087T1
- Authority
- AT
- Austria
- Prior art keywords
- glycoconjugates
- shigella flexneri
- vaccines against
- against shigella
- potential vaccines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0283—Shigella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
- A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/1228—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
- G01N33/56916—Enterobacteria, e.g. shigella, salmonella, klebsiella, serratia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Materials Engineering (AREA)
- Polymers & Plastics (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002434685A CA2434685A1 (en) | 2003-07-04 | 2003-07-04 | Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a |
CA002434668A CA2434668A1 (en) | 2003-07-04 | 2003-07-07 | Novel approach to design glycopeptides based on o-specific polysaccharide of shigella flexneri serotype 2a |
PCT/IB2004/002657 WO2005003775A2 (en) | 2003-07-04 | 2004-07-02 | Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE514087T1 true ATE514087T1 (de) | 2011-07-15 |
Family
ID=33565750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04744281T ATE514087T1 (de) | 2003-07-04 | 2004-07-02 | Glycokonjugate und ihre verwendung als potentielle impfstoffe gegen eine infektion mit shigella flexneri |
Country Status (6)
Country | Link |
---|---|
US (2) | US8124380B2 (de) |
EP (2) | EP2369345B1 (de) |
AT (1) | ATE514087T1 (de) |
CA (2) | CA2434668A1 (de) |
DK (2) | DK2369345T3 (de) |
WO (1) | WO2005003775A2 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5069920B2 (ja) * | 2007-02-08 | 2012-11-07 | 公益財団法人東京都医学総合研究所 | マンノース6−リン酸−ポリエチレングリコール結合体 |
CA2591253A1 (en) | 2007-06-05 | 2008-12-05 | Institut Pasteur | Specific oligosaccharides of shigella flexneri serotypes 3a and x, their synthesis, compositions comprising them and their uses thereof |
US9925209B2 (en) | 2008-03-19 | 2018-03-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same |
US9687559B2 (en) | 2008-03-19 | 2017-06-27 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
EP2123668A1 (de) | 2008-05-22 | 2009-11-25 | Institut Pasteur | Immunogene Polypeptide, welche das Oberflächen-Polysaccharid-O-Antigen der Serotyp 2A Shigella flexneri nachahmen, Verfahren zu ihrer Herstellung und ihre Verwendung in Impf- und Diagnosezusammensetzungen |
WO2010019890A2 (en) * | 2008-08-15 | 2010-02-18 | The Government Of The Usa, As Represented By The Secretary Of The Dept. Of Health & Human Services | Vaccine for shigella |
WO2010030342A2 (en) * | 2008-09-09 | 2010-03-18 | The Board Of Regents Of The University Of Oklahoma | Heparosan polymers and methods of making and using same for the enhancement of therapeutics |
JP5605541B2 (ja) * | 2009-03-06 | 2014-10-15 | 国立大学法人埼玉大学 | フコシルキトビオース誘導体の製造方法 |
US9358302B2 (en) | 2009-03-23 | 2016-06-07 | The Brigham And Women's Hospital, Inc. | Glycoconjugate vaccines |
EP2386563A1 (de) * | 2010-05-12 | 2011-11-16 | Institut Pasteur | Neue O-acetylierte Decasaccharide |
DK3252076T3 (da) | 2011-01-14 | 2019-12-02 | Univ California | Diagnostisk anvendelse af antistoffer mod ror-1-protein |
EP2724730A1 (de) * | 2012-10-29 | 2014-04-30 | Institut Pasteur | Glycokonjugate und deren Verwendung als potentielle Impfstoffe gegen Infektion durch Shigella flexneri |
US10307474B2 (en) | 2014-08-08 | 2019-06-04 | Glaxosmithkline Biologicals S.A. | Modified host cells and hybrid oligosaccharides for use in bioconjugate production |
CN106795194A (zh) | 2014-10-09 | 2017-05-31 | 默沙东和惠康基金会合资的希勒曼实验室私人有限公司 | 改进的缀合方法和由其获得的新的合成的寡糖‑蛋白质缀合物 |
KR20220143904A (ko) * | 2020-02-17 | 2022-10-25 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 사람 4-1bb 항진제 항체 및 이의 사용 방법 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5204098A (en) | 1988-02-16 | 1993-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-protein conjugates |
US5738855A (en) | 1994-10-17 | 1998-04-14 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Synthesis of typhoid fever vaccine from a plant or fruit polysaccharide |
AU8407298A (en) * | 1997-07-17 | 1999-02-10 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Hexadecasaccharide-protein conjugate vaccine for (shigella dysenteriae) type |
US20030170248A1 (en) * | 1997-12-23 | 2003-09-11 | Jeffrey R. Stinson | Humanized monoclonal antibodies that protect against shiga toxin induced disease |
GB9809839D0 (en) | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
WO2002080964A1 (en) | 2001-04-06 | 2002-10-17 | Institut Pasteur | Conjugate vaccine composed of the polysaccharide moiety of the lipopolysaccharide of vibrio cholerae 0139 bound to tetanus toxoid |
BRPI0308585B8 (pt) * | 2002-03-13 | 2021-05-25 | Biogen Idec Inc | anticorpo isolado ou fragmento de ligação a antígeno do mesmo que se liga à alfavbeta6, composição, método de detecção in vitro de alfavbeta6 e construção de dna |
US20030235818A1 (en) * | 2002-04-08 | 2003-12-25 | Vsevolod Katritch | Immunogenic peptides, and method of identifying same |
JP2007525409A (ja) | 2003-01-08 | 2007-09-06 | アプライド モレキュラー エボリューション,インコーポレイテッド | TNF−α結合分子 |
-
2003
- 2003-07-07 CA CA002434668A patent/CA2434668A1/en not_active Abandoned
-
2004
- 2004-07-02 WO PCT/IB2004/002657 patent/WO2005003775A2/en active Application Filing
- 2004-07-02 US US10/563,221 patent/US8124380B2/en active Active
- 2004-07-02 EP EP10011475.0A patent/EP2369345B1/de active Active
- 2004-07-02 DK DK10011475.0T patent/DK2369345T3/en active
- 2004-07-02 EP EP04744281A patent/EP1642132B1/de active Active
- 2004-07-02 DK DK04744281.9T patent/DK1642132T3/da active
- 2004-07-02 AT AT04744281T patent/ATE514087T1/de not_active IP Right Cessation
- 2004-07-02 CA CA2470262A patent/CA2470262C/en active Active
-
2011
- 2011-12-14 US US13/325,511 patent/US9446109B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US8124380B2 (en) | 2012-02-28 |
WO2005003775A9 (en) | 2008-11-06 |
DK2369345T3 (en) | 2015-01-12 |
EP1642132A2 (de) | 2006-04-05 |
US20140161793A2 (en) | 2014-06-12 |
CA2434668A1 (en) | 2005-01-04 |
EP2369345A1 (de) | 2011-09-28 |
US20130243751A1 (en) | 2013-09-19 |
EP1642132B1 (de) | 2011-06-22 |
US9446109B2 (en) | 2016-09-20 |
EP2369345B1 (de) | 2014-10-01 |
CA2470262C (en) | 2013-01-08 |
WO2005003775A2 (en) | 2005-01-13 |
WO2005003775A3 (en) | 2005-05-06 |
US20080112951A1 (en) | 2008-05-15 |
CA2470262A1 (en) | 2005-01-04 |
DK1642132T3 (da) | 2011-10-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE514087T1 (de) | Glycokonjugate und ihre verwendung als potentielle impfstoffe gegen eine infektion mit shigella flexneri | |
ATE532772T1 (de) | Piperazinderivate und deren verwendung als therapeutische mittel | |
CY1107609T1 (el) | Απεικoνιση, διaγνωση και θεραπεiα ασθeνειας | |
DK1409544T3 (da) | Humane DR4-antistoffer og anvendelser deraf | |
CY1109784T1 (el) | Υποκατεστημενα γλουταριμιδια και η χρησιμοποιηση τους σαν αναστολεις της il-12 παραγωγης | |
EA200700202A1 (ru) | Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей | |
TR200001264T2 (tr) | Alzheimer hastalığının antermotem teşhisi için bileşikler. | |
ATE555789T1 (de) | Pyridazinderivate und deren verwendung als therapeutische mittel | |
DK1141235T3 (da) | Bifidobakterier til behandling af inflammatorisk sygdom | |
CY1109151T1 (el) | Αντισωματα dr4 και χρησεις αυτων | |
EA200702575A1 (ru) | Иммуногенная композиция | |
CY1110745T1 (el) | Παραγωγα πυρρολιδονης ως αναστολεις μαοβ | |
DK1053256T3 (da) | Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf | |
ATE245152T1 (de) | Dioxocyclopentylhydroxamsäure | |
ATE337014T1 (de) | Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen | |
DE60312838D1 (de) | 1,2,3,4,7,8-HEXAHYDRO-6H-c1,4ÜDIAZEPINOc6,7,1-1JÜCHINOLINDERIVATIVE ALS ANTIPSYCHOTIKA UND MITTEL GEGEN OBESITAS | |
DE602004031410D1 (de) | Inden derivate als pharmazeutika | |
EE200200281A (et) | Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks | |
NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
DE60229287D1 (de) | Pharmazeutische zubereitung zur oralen verwendung von heparin und seinen derivaten | |
DE602004017326D1 (de) | Tetrahydrocarbazolderivate und deren pharmazeutische verwendung | |
NO20044550L (no) | Heterotrisyklyl 6-alkaliden-penemer som beta-laktamaseinhibitorer | |
DE60231143D1 (de) | Organische verbindungen | |
EA200400409A1 (ru) | Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их | |
FR2864083B1 (fr) | Nouveaux derives d'acides phenyl-boroniques et leurs procedes de preparation. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |